GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensysce Biosciences Inc (NAS:ENSC) » Definitions » ROC (Joel Greenblatt) %

Ensysce Biosciences (Ensysce Biosciences) ROC (Joel Greenblatt) % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ensysce Biosciences ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Ensysce Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Ensysce Biosciences's ROC (Joel Greenblatt) % or its related term are showing as below:

ENSC's ROC (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -333.28
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Ensysce Biosciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Ensysce Biosciences ROC (Joel Greenblatt) % Historical Data

The historical data trend for Ensysce Biosciences's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensysce Biosciences ROC (Joel Greenblatt) % Chart

Ensysce Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
- - - -

Ensysce Biosciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ensysce Biosciences's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Ensysce Biosciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ensysce Biosciences's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensysce Biosciences's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Ensysce Biosciences's ROC (Joel Greenblatt) % falls into.



Ensysce Biosciences ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.067) - (2.478 + 0 + 0)
=-1.411

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.197) - (1.39 + 0 + 0)
=-0.193

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Ensysce Biosciences for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-7.472/( ( (0 + max(-1.411, 0)) + (0 + max(-0.193, 0)) )/ 1 )
=-7.472/( ( 0 + 0 )/ 1 )
=-7.472/0
= %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ensysce Biosciences  (NAS:ENSC) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Ensysce Biosciences ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Ensysce Biosciences's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ensysce Biosciences (Ensysce Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
7946 Ivanhoe Avenue, Suite 201, La Jolla, CA, USA, 92037
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the?Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform.
Executives
Bob G Gower director 402 TIMBERWILDE LANE, HOUSTON TX 77024
Lynn Kirkpatrick director, officer: Chief Executive Officer 110 110TH AVENUE NE, SUITE 685, BELLEVUE WA 98004
Nilab Osman officer: Chief Medical Officer C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Lee M. Rauch director C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Linda Pestano officer: Chief Development Officer 7946 IVANHOE AVENUE, LA JOLLA CA 92037
Kevin Geoffrey Birkett officer: Chief Commercial Officer 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
William K Schmidt officer: Chief Medical Officer TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
David Carl Humphrey officer: Chief Financial Officer 4767 NEXUS CENTRE DR, SAN DIEGO CA 92121
William H Chang director, 10 percent owner C/O SEMLER SCIENTIFIC, INC., 911 BERN COURT, SUITE 110, SAN JOSE CA 95112
Andrew Benton director 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Adam Levin director 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Jeffrey Millard officer: Chief Operating Officer 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Richard Chester Wright officer: Chief Business Officer 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Steven Robert Martin director 11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Curtis Rosebraugh director 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037